Avelumab in First-line NSCLC (JAVELIN Lung 100)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02576574. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.
Study identification
- NCT ID
- NCT02576574
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,214 participants
Conditions and interventions
Conditions
Interventions
- Avelumab Drug
- Pemetrexed Drug
- Paclitaxel Drug
- Gemcitabine Drug
- Carboplatin Drug
- Cisplatin Drug
- Avelumab Weekly Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2015 (Actual)
- Primary completion
- Dec 6, 2021 (Actual)
- Completion
- Jan 29, 2024 (Actual)
- Last update posted
- Jan 31, 2025
2015 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| Arizona Center for Cancer Care | Surprise | Arizona | 85374 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| University Cancer Institute | Boynton Beach | Florida | 33426 | — |
| South Georgia Medical Center | Valdosta | Georgia | 31602 | — |
| Christus Cancer Treatment Center | Shreveport | Louisiana | 71105 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Novant Health Oncology Specialists | Kernersville | North Carolina | 27284 | — |
| Mercy Research | Oklahoma City | Oklahoma | 73120 | — |
| Kaiser Permanente Northwest | Portland | Oregon | 97227 | — |
| Lancaster Cancer Center | Lancaster | Pennsylvania | 17605 | — |
| Cookeville Regional Medical Center | Cookeville | Tennessee | 38501 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
| Coastal Bend Cancer Center | Corpus Christi | Texas | 78404 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401-1473 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
| Cheyenne Regional Medical Center | Cheyenne | Wyoming | 82001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 328 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02576574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 31, 2025 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.